Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3JFIH)

• Drug Name: Vancomycin Drug Info
• Synonyms: Vancomycin (oral, MRSA), AuricX; Vancomycin (oral/pill, MSRA); Vancomycin (oral/pill, MSRA), AuricX/SRI International

Indication

Disease Entry	ICD 11	Status	REF
Bacteremia	1A73	Approved	[1]
Bacterial endocarditis		Approved	[1]
Clostridioides difficile infection	1A04	Approved	[1]
Methicillin-resistant staphylococci infection	1A00-1A09	Approved	[2]
Neonatal sepsis		Approved	[1]
Staphylococcal pneumonia		Approved	[1]
Staphylococcus aureus infection		Approved	[1]
MRSA infection	1D01.0Y	Investigative	[3]
Skin infection	1F28-1G0Z	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 14969
  ChEBI ID: CHEMBL262777
  CAS Number: CAS 1404-90-6
  TTD Drug ID: DM3JFIH

Molecule-Related Drug Atlas

Drug(s) Metabolized By VanA ligase (vanA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teicoplanin	DMAQ2LK	Bacterial infection	1A00-1C4Z	Approved	[4]
Teicoplanin	DMAQ2LK	Bacterial infection	1A00-1C4Z	Approved	[4]
Teicoplanin	DMAQ2LK	Bacterial infection	1A00-1C4Z	Approved	[4]
Teicoplanin	DMAQ2LK	Bacterial infection	1A00-1C4Z	Approved	[5]
Teicoplanin	DMAQ2LK	Bacterial infection	1A00-1C4Z	Approved	[6]

Drug(s) Affected By C-reactive protein (CRP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[13]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[14]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[15]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[16]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[17]
Acalabrutinib	DM7GCVW	leukaemia	2A60-2B33	Approved	[18]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[19]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[20]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[21]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[22]

Drug(s) Affected By HLA class II histocompatibility antigen, DM beta chain (HLA-DMB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[12]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[23]
Valdecoxib	DMAY7H4	Osteoarthritis	FA00-FA05	Approved	[12]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Ethosuximide	DMDZ9LT	Epilepsy	8A60-8A68	Approved	[12]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[25]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[26]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[27]
Bortezomib	DMNO38U	Leukemia		Approved	[28]
Famotidine	DMRL3AB	Gastric ulcer	DA60	Approved	[12]

Drug(s) Affected By Major histocompatibility complex class I-related gene protein (MR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[12]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[29]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[12]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[30]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[12]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[31]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[12]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[12]
Repaglinide	DM5SXUV	Diabetic complication	5A2Y	Approved	[12]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[32]

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
VanA ligase (vanA)	DEOFMQ7	Q0WYK7_ENTFL	Substrate	[4]
VanA ligase (vanA)	DEO97D6	VANA_ENTFC	Substrate	[4]
VanA ligase (vanA)	DEN6VO0	A0A376GZ73_ENTGA	Substrate	[5]
VanA ligase (vanA)	DEO8E75	A0A437UFE2_ENTAV	Substrate	[4]
VanA ligase (vanA)	DESOXHP	A0A4U9YK96_ENTCA	Substrate	[6] , [5]
VanB ligase (vanB)	DER7KFQ	VANB_ENTFA	Substrate	[4]
VanB ligase (vanB)	DE27YVU	Q58F99_ENTFC	Substrate	[4]
VanG ligase (vanG)	DEPN8F9	A0A076YRI6_STRAG	Substrate	[7]
VanC2 ligase (vanC)	DEIF4P9	VANC_ENTGA	Substrate	[8]
D-alanylalanine synthetase (ddl)	DE035GU	A0A1Q6S944_9FIRM	Substrate	[7]
VanB ligase (vanB)	DEMDEJ8	Q58F99_ENTFC	Substrate	[9]
VanB ligase (vanB)	DE2GMEK	Q58F99_ENTFC	Substrate	[9]
VanC2 ligase (vanC)	DEH73ZC	Q47720_ENTCA	Substrate	[10]
VanG ligase (vanG)	DEPH3S7	A0A076ZC24_STRAP	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Gene/Protein Processing	[11]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB)	OT17HGXJ	DMB_HUMAN	Gene/Protein Processing	[12]
Major histocompatibility complex class I-related gene protein (MR1)	OTZU3XX7	HMR1_HUMAN	Gene/Protein Processing	[12]

References

• [1] Vancomycin FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [4] Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
• [5] Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother. 1994 Jul;38(7):1675-7.
• [6] vanA in Enterococcus faecium, Enterococcus faecalis, and Enterococcus casseliflavus detected in French cattle. Foodborne Pathog Dis. 2009 Nov;6(9):1107-11.
• [7] vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio. 2014 Jul 22;5(4):e01386-14.
• [8] Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine:D-alanine ligase-related protein necessary for vancomycin resistance. Gene. 1992 Mar 1;112(1):53-8.
• [9] vanI: a novel D-Ala-D-Lac vancomycin resistance gene cluster found in Desulfitobacterium hafniense. Microb Biotechnol. 2014 Sep;7(5):456-66.
• [10] Bacterial resistance to vancomycin: overproduction, purification, and characterization of VanC2 from Enterococcus casseliflavus as a D-Ala-D-Ser ligase. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10040-4.
• [11] [Successful treatment of MRSA-associated glomerulonephritis with antibiotic therapy]. Nihon Jinzo Gakkai Shi. 2003;45(1):37-41.
• [12] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [13] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [14] C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS. 2004 Dec 3;18(18):2434-7.
• [15] Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004 Aug;44(2):180-5. doi: 10.1161/01.HYP.0000133310.42762.25. Epub 2004 Jun 7.
• [16] The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol. 2007 Feb 28;557(2-3):221-9.
• [17] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [18] Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020 Jun 5;5(48):eabd0110. doi: 10.1126/sciimmunol.abd0110. Epub 2020 Jun 5.
• [19] The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Curr Med Res Opin. 1975;3(5):286-97. doi: 10.1185/03007997509114779.
• [20] Intractable insomnia after cessation of treatment with thalidomide. Gastroenterology. 2001 May;120(6):1567-8. doi: 10.1053/gast.2001.24495.
• [21] Effects of hormone treatment on hemostasis variables. Climacteric. 2007 Oct;10 Suppl 2:32-7. doi: 10.1080/13697130701598548.
• [22] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [23] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [24] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [25] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [26] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [27] Chromosomal radiosensitivity in two cell lineages derived from clinically radiosensitive cancer patients. Clin Cancer Res. 2005 Sep 1;11(17):6352-8. doi: 10.1158/1078-0432.CCR-04-1931.
• [28] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [29] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [30] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [31] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [32] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.